Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Novartis' Rhapsido touts solid efficacy with industry-best safety data in RMS phase 3 reveal

26 October 2026 · By · Wire by Fusion42

Published

26 October 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercepharma.com →

◆ Verified

Fusion42 · 26 October 2026 · Fusion42 review

Novartis announced positive phase 3 results for its BTK inhibitor Rhapsido in relapsing multiple sclerosis, demonstrating significant relapse reduction and a strong safety profile with no liver toxicity. The company plans to seek global regulatory approval supported by data from over 2,000 patients across two major trials.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You face new competition from a safer MS drug that avoids liver toxicity concerns that stalled rivals. This opens a chance to pivot or partner around safer BTK inhibitors as regulators warm to this class globally.

◆ Coverage

1 source · 26 Oct 2026

◆ Related on Wire

◆ Topics

Biotechms-treatmentbtk-inhibitorphase-3-resultsdrug-approvalsafety-data